Cell Therapy Manufacturing & Gene Therapy Congress is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Kai Pinkernell
Chief Medical Officer (CMO) & Chief Development Officer at Medigene

Profile

Dr. Kai Pinkernell is the Chief Medical Officer/Chief Development Officer at Medigene AG and responsible for the areas of Clinical Affairs, RA/QA and CMC. Medigene AG is a stock listed (Frankfurt: MDG1, Prime Standard) biotechnology company with its headquarters in Martinsried, Munich. Medigene concentrates on the development of personalized T cell-based immunotherapies with projects in pre-clinical and clinical development.
Previously, until January 2016, Dr. Pinkernell was the Global Head of Clinical Business at Miltenyi Biotec GmbH, leading clinical marketing, sales and development, worldwide. Also, Dr. Pinkernell has been with Cytori Therapeutics Inc., San Diego, USA, from 2005 to 2009, as Senior Director of Regenerative Cell Technology and Clinical Applications Director. Furthermore, he has been a Researcher of cell therapy approaches in cardiovascular applications at Tulane University, New Orleans, USA. He received his medical degree from the Westfaelische-Wilhems University in Muenster, Germany, and pursued a residency/fellowship in internal medicine/cardiology at the German Heart Center and Klinikum Rechts der Isar, Technical University, in Munich, Germany. He further received a Master of Business Administration from the Marshall School of Business at the University of Southern California, Los Angeles, USA. Dr. Pinkernell has been active in the research, development and commercialization of cell and gene therapies since 1999 in various fields.

Kai Pinkernell's Network

Agenda Sessions

  • Using Cutting-edge Technologies to Develop TCR-based Immunotherapies

    , 11:15